Effectiveness of low-dose nadolol for ventricular arrhythmias

Morganroth, Joel; Duchin, Kenneth L.

doi:10.1016/0002-9149(86)90061-5

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The C max (22–152 ng/mL) was increased linearly as the dose was increased from 10, 20, 40 and 80 mg. The mean AUC values were 414, 282 and 2154 (ng h/ml) after administration of 10, 20, and 40 mg, doses of nadolol, respectively 29 …”

Section: Resultsmentioning

confidence: 94%

“…Among lactating females, the nadolol concentration in milk was 4.6 times higher than the serum 17 therefore, caution should be taken in lactating mothers treated with nadolol. The effectiveness of low‐dose nadolol for ventricular arrhythmias was studied and concluded that 20 mg/kg was effective in the majority of the patients 29 . The results of a study on paediatrics indicated that the elimination of nadolol was more rapid in infants than the adults.…”

Section: Discussionmentioning

confidence: 99%

“…The effectiveness of lowdose nadolol for ventricular arrhythmias was studied and concluded that 20 mg/kg was effective in the majority of the patients. 29 The results of a study on paediatrics indicated that the elimination of nadolol was more rapid in infants than the adults. Higher variability could be seen in PK of nadolol during the first year of life, that's why it is recommended that close monitoring should be done during treatment with nadolol in infants.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical pharmacokinetics of nadolol: A systematic review

Kalsoom

Zamir

Rehman

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective: Nadolol is a non-selective beta-adrenergic antagonist that is used for the treatment of hypertension and angina. The primary route for its administration is oral. It is given once daily as it has a longer half-life (t½). The purpose of conducting this systematic review is to provide a comprehensive view of all the available pharmacokinetic (PK) data on nadolol in humans. This review aimed to systematically collate and analyze publish data on the clinical PK of nadolol in humans and this can be beneficial for the clinicians in dosage adjustments.Methods: Two electronic databases PubMed and Google Scholar were used for conducting a systematic literature search. All the relevant articles containing PK data of nadolol in humans were retrieved. A total of 1275 articles were searched from both databases and after applying eligibility criteria finally, 22 articles were included for conducting the systematic review.Results and discussion: The area under the plasma concentration curve (AUC) and maximum plasma concentration (C max ) of nadolol increased in a dose-dependent manner. The t½ of nadolol was increased to double (18.2-68.6 h) in the patients with chronic kidney disease while the serum t½ became shorter (3.2-4.3 h) when administered to the children. The bioavailability of nadolol was greatly reduced by the coadministration of green tea. Nadolol can be effectively removed by hemodialysis. It undergoes enterohepatic circulation thus activated charcoal decreased its bioavailability.What is new and conclusion: Since, there is no previous report of a systematic review on the PK of nadolol, the current review encompasses all the relevant published articles on nadolol in humans. The analysis and understanding of PK parameters (AUC, C max , and t½) of nadolol may be helpful in the development and evaluation of PK models.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation